Spark Therapeutics Inc. (ONCE) Trading Down 4.5%
Spark Therapeutics Inc. (NASDAQ:ONCE) fell 4.5% on Tuesday . The company traded as low as $58.84 and last traded at $61.00, with a volume of 824,134 shares changing hands. The stock had previously closed at $63.87.
A number of brokerages recently weighed in on ONCE. Jefferies Group reiterated a “hold” rating on shares of Spark Therapeutics in a report on Sunday, June 12th. Cowen and Company reissued a “buy” rating and set a $75.00 target price on shares of Spark Therapeutics in a research report on Wednesday, May 4th. Chardan Capital set a $35.00 target price on shares of Spark Therapeutics and gave the company a “hold” rating in a research report on Thursday, July 21st. Wedbush reissued an “underperform” rating and set a $29.00 target price (up previously from $28.00) on shares of Spark Therapeutics in a research report on Wednesday, August 10th. Finally, Zacks Investment Research raised shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Friday, April 29th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. Spark Therapeutics has an average rating of “Hold” and an average target price of $61.20.
The stock has a 50-day moving average price of $55.95 and a 200 day moving average price of $42.53. The stock’s market cap is $1.78 billion.
Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by $0.07. The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.17 million. During the same quarter in the prior year, the firm earned ($0.60) earnings per share. Spark Therapeutics’s revenue was up .0% compared to the same quarter last year. On average, analysts forecast that Spark Therapeutics Inc. will post ($3.84) earnings per share for the current year.
In other news, insider Katherine A. High sold 500 shares of the stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $60.24, for a total transaction of $30,120.00. Following the sale, the insider now owns 242,290 shares of the company’s stock, valued at $14,595,549.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 900 shares of the stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $60.24, for a total transaction of $54,216.00. Following the sale, the chief executive officer now directly owns 230,100 shares in the company, valued at approximately $13,861,224. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Spark Therapeutics stock. RS Investment Management Co. LLC raised its stake in Spark Therapeutics Inc. (NASDAQ:ONCE) by 2.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 452,349 shares of the company’s stock after buying an additional 9,957 shares during the period. RS Investment Management Co. LLC owned approximately 1.83% of Spark Therapeutics worth $20,496,000 as of its most recent SEC filing.
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.